Cargando…
Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once considered a niche area of academic research, ATMPs now represent one of the fastest-growing areas of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509731/ https://www.ncbi.nlm.nih.gov/pubmed/33015538 http://dx.doi.org/10.1177/2515135520944355 |
_version_ | 1783585657258508288 |
---|---|
author | Pillai, Manon Davies, Michelle M. Thistlethwaite, Fiona C. |
author_facet | Pillai, Manon Davies, Michelle M. Thistlethwaite, Fiona C. |
author_sort | Pillai, Manon |
collection | PubMed |
description | Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once considered a niche area of academic research, ATMPs now represent one of the fastest-growing areas of clinical development. The field has seen a rapid expansion of academic and commercial entities successfully translating ATMP research into the clinic. This is reflected in projection that the global gene and cell therapy market will be worth US $11.96 billion by 2025. However, these treatments are complex to deliver and frequently do not fit naturally into established healthcare systems. In the United Kingdom (UK) there has been a long-standing interest in ATMP research and, in order to meet the ambition to act as an international hub of activity for delivery of ATMPs, a collaborative network of Advanced Therapy Treatment Centres (ATTCs) has been established. This review explores the challenges of delivery in the clinical setting, focussing on one form of ATMP, Adoptive Cell Therapy (ACT). We describe the strategy being implemented in the UK to optimise the roll-out of these exciting new therapies. |
format | Online Article Text |
id | pubmed-7509731 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-75097312020-10-01 Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites Pillai, Manon Davies, Michelle M. Thistlethwaite, Fiona C. Ther Adv Vaccines Immunother Review Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once considered a niche area of academic research, ATMPs now represent one of the fastest-growing areas of clinical development. The field has seen a rapid expansion of academic and commercial entities successfully translating ATMP research into the clinic. This is reflected in projection that the global gene and cell therapy market will be worth US $11.96 billion by 2025. However, these treatments are complex to deliver and frequently do not fit naturally into established healthcare systems. In the United Kingdom (UK) there has been a long-standing interest in ATMP research and, in order to meet the ambition to act as an international hub of activity for delivery of ATMPs, a collaborative network of Advanced Therapy Treatment Centres (ATTCs) has been established. This review explores the challenges of delivery in the clinical setting, focussing on one form of ATMP, Adoptive Cell Therapy (ACT). We describe the strategy being implemented in the UK to optimise the roll-out of these exciting new therapies. SAGE Publications 2020-09-20 /pmc/articles/PMC7509731/ /pubmed/33015538 http://dx.doi.org/10.1177/2515135520944355 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Pillai, Manon Davies, Michelle M. Thistlethwaite, Fiona C. Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites |
title | Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites |
title_full | Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites |
title_fullStr | Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites |
title_full_unstemmed | Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites |
title_short | Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites |
title_sort | delivery of adoptive cell therapy in the context of the health-care system in the uk: challenges for clinical sites |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509731/ https://www.ncbi.nlm.nih.gov/pubmed/33015538 http://dx.doi.org/10.1177/2515135520944355 |
work_keys_str_mv | AT pillaimanon deliveryofadoptivecelltherapyinthecontextofthehealthcaresystemintheukchallengesforclinicalsites AT daviesmichellem deliveryofadoptivecelltherapyinthecontextofthehealthcaresystemintheukchallengesforclinicalsites AT thistlethwaitefionac deliveryofadoptivecelltherapyinthecontextofthehealthcaresystemintheukchallengesforclinicalsites |